Simply Wall St.
A Look At CytomX Therapeutics (CTMX) Valuation After Positive Varsetatug Masetecan Phase 1 Expansion Results
📊
AI Sentiment
Positive
7/10
- Home
- CTMX
as of 03-23-2026 3:53pm EST
$4.47
+$0.02
+0.45%
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.
| Founded: | 2008 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 596.2M | IPO Year: | 2015 |
| Target Price: | $11.90 | AVG Volume (30 days): | 9.4M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 10 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | N/A | EPS Growth: | N/A |
| 52 Week Low/High: | $0.40 - $8.21 | Next Earning Date: | 03-16-2026 |
| Revenue: | $76,201,000 | Revenue Growth: | -44.82% |
| Revenue Growth (this year): | -64.57% | Revenue Growth (next year): | 27.22% |
| P/E Ratio: | 22.58 | Index: | N/A |
| Free Cash Flow: | -75807000.0 | FCF Growth: | N/A |
AI-Powered CTMX Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated a day ago
AI Recommendation
hold
Model Accuracy: 72.67%
72.67%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of CytomX Therapeutics Inc. (CTMX)
McCarthy Sean A.
Sell
CEO
CTMX Mar 17, 2026
Avg Cost/Share
$6.42
Shares
118,969
Total Value
$764,137.89
Owned After
1,078,922
SEC Form 4
Ogden Christopher
Sell
Chief Financial Officer
CTMX Mar 17, 2026
Avg Cost/Share
$6.42
Shares
19,323
Total Value
$124,111.63
Owned After
296,948
SEC Form 4
BELVIN MARCIA
Sell
SVP, Chief Scientific Officer
CTMX Mar 17, 2026
Avg Cost/Share
$6.42
Shares
31,492
Total Value
$202,273.12
Owned After
300,760
SEC Form 4
Chu Yu-Waye
Sell
Chief Medical Officer
CTMX Mar 17, 2026
Avg Cost/Share
$6.42
Shares
21,279
Total Value
$136,675.02
Owned After
189,446
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| McCarthy Sean A. | CTMX | CEO | Mar 17, 2026 | Sell | $6.42 | 118,969 | $764,137.89 | 1,078,922 | |
| Ogden Christopher | CTMX | Chief Financial Officer | Mar 17, 2026 | Sell | $6.42 | 19,323 | $124,111.63 | 296,948 | |
| BELVIN MARCIA | CTMX | SVP, Chief Scientific Officer | Mar 17, 2026 | Sell | $6.42 | 31,492 | $202,273.12 | 300,760 | |
| Chu Yu-Waye | CTMX | Chief Medical Officer | Mar 17, 2026 | Sell | $6.42 | 21,279 | $136,675.02 | 189,446 |
Earnings Transcripts
SEC 8-K filings with transcript text
2025 Q4 Q4 2025 Earnings
8-K BUY Mar 16, 2026 · 100% conf.
2025
Q4
Q4 2025 Earnings
8-K BUYMar 16, 2026 · 100% conf.
AI Prediction BUY
1D
+64.70%
$11.02
Act: -18.46%
5D
+70.30%
$11.39
20D
+82.47%
$12.21
Price: $6.69 Prob +5D: 100% AUC: 1.000
0001193125-26-107152
8-K
0001501989false00015019892026-03-162026-03-16
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 16, 2026
CytomX Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter)
Delaware
001-37587
27-3521219
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)
151 Oyster Point Blvd Suite 400
South San Francisco, California
94080
(Address of Principal Executive Offices)
(Zip Code)
Registrant’s Telephone Number, Including Area Code: 650 515-3185
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, $0.00001 par value per share
CTMX
Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition. On March 16, 2026, CytomX Therapeutics, Inc., a Delaware corporation (the “Company”) issued a press release reporting its financial results for the year ended December 31, 2025. A copy of the press release is furnished herewith as Exhibit 99.1. The information in Item 2.02 of this Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item 2.02 and in the accompanying Exhibit 99.1 shall not be incorporated by reference into any filing with the Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing. Item 9.01 Financial Statements and Exhibits. (d) Exhibits. The following exhibit is furnished as part of this report.
Exhibit No.
Description
99.1
Press release titled "CytomX Therapeutics Announces 2025 Financial Results and Provides Business Update" issued by CytomX Therapeutics, Inc. on March 16, 2026.
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
CYTOMX THERAPEUTICS, INC.
Date:
March 16, 2026
By:
/s/ Christopher W. Ogden
Christopher W. Ogden Chief Financial Officer
2025 Q3 Q3 2025 Earnings
8-K SELL Nov 6, 2025 · 100% conf.
2025
Q3
Q3 2025 Earnings
8-K SELLNov 6, 2025 · 100% conf.
AI Prediction SELL
1D
-0.84%
$4.17
Act: -13.91%
5D
-7.04%
$3.91
Act: -8.20%
20D
-1.34%
$4.15
Act: -6.06%
Price: $4.21 Prob +5D: 0% AUC: 1.000
0001193125-25-269533
8-K
0001501989false00015019892025-11-062025-11-06
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 06, 2025
CytomX Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter)
Delaware
001-37587
27-3521219
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)
151 Oyster Point Blvd Suite 400
South San Francisco, California
94080
(Address of Principal Executive Offices)
(Zip Code)
Registrant’s Telephone Number, Including Area Code: 650 515-3185
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, $0.00001 par value per share
CTMX
Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition. On November 6, 2025, CytomX Therapeutics, Inc., a Delaware corporation (the “Company”) issued a press release reporting its unaudited financial results for the three and nine months ended September 30, 2025. A copy of the press release is furnished herewith as Exhibit 99.1. The information in Item 2.02 of this Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item 2.02 and in the accompanying Exhibit 99.1 shall not be incorporated by reference into any filing with the Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing. Item 9.01 Financial Statements and Exhibits. (d) Exhibits. The following exhibit is furnished as part of this report.
Exhibit No.
Description
99.1
Press release titled "CytomX Therapeutics Announces Third Quarter of 2025 Financial Results and Provides Business Update" issued by CytomX Therapeutics, Inc. on November 6, 2025.
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
CYTOMX THERAPEUTICS, INC.
Date:
November 6, 2025
By:
/s/ Christopher W. Ogden
Christopher W. Ogden Chief Financial Officer
2025 Q2 Q2 2025 Earnings
8-K Aug 7, 2025
2025
Q2
Q2 2025 Earnings
8-KAug 7, 2025
0000950170-25-105053
8-K
0001501989false00015019892025-08-072025-08-07
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 07, 2025
CytomX Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter)
Delaware
001-37587
27-3521219
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)
151 Oyster Point Blvd Suite 400
South San Francisco, California
94080
(Address of Principal Executive Offices)
(Zip Code)
Registrant’s Telephone Number, Including Area Code: 650 515-3185
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, $0.00001 par value per share
CTMX
Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition. On August 7, 2025, CytomX Therapeutics, Inc., a Delaware corporation (the “Company”) issued a press release reporting its unaudited financial results for the three and six months ended June 30, 2025. A copy of the press release is furnished herewith as Exhibit 99.1. The information in Item 2.02 of this Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item 2.02 and in the accompanying Exhibit 99.1 shall not be incorporated by reference into any filing with the Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing. Item 9.01 Financial Statements and Exhibits. (d) Exhibits. The following exhibit is furnished as part of this report.
Exhibit No.
Description
99.1
Press release titled "CytomX Therapeutics Announces Second Quarter of 2025 Financial Results and Provides Business Update" issued by CytomX Therapeutics, Inc. on August 7, 2025.
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
CYTOMX THERAPEUTICS, INC.
Date:
August 7, 2025
By:
/s/ Christopher W. Ogden
Christopher W. Ogden Chief Financial Officer
Latest CytomX Therapeutics Inc. News
CTMX Breaking Stock News: Dive into CTMX Ticker-Specific Updates for Smart Investing
Insider Monkey
Jefferies Raises CytomX Therapeutics (CTMX) Price Target to $16
📈
AI Sentiment
Highly Positive
9/10
MT Newswires
Cytomx Therapeutics Insider Sold Shares Worth $764,138, According to a Recent SEC Filing
📉
AI Sentiment
Negative
3/10
MT Newswires
Sector Update: Health Care Stocks Lower in Afternoon Trading
📉
AI Sentiment
Negative
3/10
MT Newswires
Sector Update: Health Care Stocks Decline Premarket Wednesday
📉
AI Sentiment
Negative
3/10
MT Newswires
CytomX Therapeutics Prices $250 Million Securities Offering; Shares Up Pre-Bell
➖
AI Sentiment
Neutral
5/10
GlobeNewswire
CytomX Therapeutics Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded Warrants
📊
AI Sentiment
Positive
6/10
Compare CTMX vs Leading Stocks
See how CTMX stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "CTMX CytomX Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.